key: cord-0785154-9hv6895j
authors: Yokoyama, Yujiro; Briasoulis, Alexandros; Takagi, Hisato; Kuno, Toshiki
title: Effect of Remdesivir on Patients with COVID-19: A Network Meta-Analysis of Randomized Control Trials
date: 2020-08-19
journal: Virus Res
DOI: 10.1016/j.virusres.2020.198137
sha: 6aef97f77a8a86f4351296b2764038012e5de050
doc_id: 785154
cord_uid: 9hv6895j

• We did network meta-analyses comparing clinical improvement of COVID-19 patients; • We compared 5-day course vs. 10-day course of remdesivir vs standard care. • Clinical improvement was higher in 5-day and 10-day course than standard care. • Clinical improvement was higher in 5-day than 10-day remdesivir.

Remdesivir is a monophosphoramidate prodrug that has a broad antiviral spectrum including coronaviruses and inhibits all human and animal coronaviruses in vitro. Several randomized controlled trials (RCTs) were conducted to investigate the effect of remdesivir for patients with COVID-19, but their results were conflicting. Thus, we conducted a network meta-analysis comparing the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care. 

Remdesivir is a monophosphoramidate prodrug that has a broad antiviral spectrum including coronaviruses and inhibits all human and animal coronaviruses in vitro [1] . Several randomized controlled trials (RCTs) were conducted to investigate the effect of remdesivir for patients with COVID-19, but their results were conflicting [2] [3] [4] [5] . Thus, we conducted a network meta-analysis Then, we performed network meta-analysis using "netmeta" 3. and 7=not hospitalized) in two [4, 5] . A Pooled analysis demonstrated that the rate of clinical improvement was significantly higher in the 5-day remdesivir group and 10-day remdesivir Figure 1B ). Our analysis demonstrated that the use of remdesivir for patients with COVID-19 was associated with the significantly higher clinical improvement rate compared with standard care alone. In addition, the rate of clinical improvement was significantly higher in the 5-day group compared with the 10-day group. We could not analyze other outcomes including mortality and safety outcomes since these were not reported in the press release of the second SIMPLE trial [5] . The full data of the trial in a peer-reviewed journal is expected for better understanding of the effect of remdesivir on patients with COVID-19. OR=odds ratio.

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

Network meta-analysis using R: a review of currently available automated packages